IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lessened its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 12.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 30,397 shares of the medical research company's stock after selling 4,463 shares during the quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp's holdings in IQVIA were worth $7,203,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in IQV. PGGM Investments boosted its position in shares of IQVIA by 55.8% during the 2nd quarter. PGGM Investments now owns 12,073 shares of the medical research company's stock worth $2,553,000 after purchasing an additional 4,326 shares during the period. Simplify Asset Management Inc. boosted its position in shares of IQVIA by 67.8% during the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company's stock worth $2,284,000 after buying an additional 3,894 shares during the period. Raymond James & Associates grew its stake in shares of IQVIA by 0.7% in the second quarter. Raymond James & Associates now owns 800,374 shares of the medical research company's stock valued at $169,231,000 after buying an additional 5,417 shares in the last quarter. Versor Investments LP purchased a new stake in shares of IQVIA in the 3rd quarter valued at $1,328,000. Finally, Gradient Investments LLC lifted its stake in IQVIA by 15.6% during the 2nd quarter. Gradient Investments LLC now owns 45,401 shares of the medical research company's stock worth $9,600,000 after acquiring an additional 6,134 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Performance

Shares of IQVIA stock traded up $0.95 on Monday, hitting $201.79. The stock had a trading volume of 1,867,915 shares, compared to its average volume of 1,177,624. The stock has a market cap of $36.62 billion, a price-to-earnings ratio of 26.48, a P/E/G ratio of 2.07 and a beta of 1.51. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The company's 50 day moving average price is $217.89 and its 200 day moving average price is $225.88. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76.

Analysts Set New Price Targets

Several research firms have recently commented on IQV. Morgan Stanley lowered their price objective on shares of IQVIA from $280.00 to $265.00 and set an "overweight" rating for the company in a research note on Monday, November 4th. Leerink Partners reissued an "outperform" rating and issued a $248.00 price target (down previously from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Barclays reduced their price objective on IQVIA from $260.00 to $255.00 and set an "overweight" rating on the stock in a research note on Friday, November 1st. StockNews.com cut IQVIA from a "buy" rating to a "hold" rating in a research note on Thursday. Finally, TD Cowen reduced their price target on IQVIA from $270.00 to $255.00 and set a "buy" rating on the stock in a research report on Friday, November 1st. Five equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $256.50.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.